The Monkeypox drugs in development market research report provides comprehensive information on the therapeutics under development for Monkeypox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Monkeypox. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Monkeypox - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Monkeypox and features dormant and discontinued products.

GlobalData tracks 23 drugs in development for Monkeypox by 19 companies/universities/institutes. The top development phase for Monkeypox is preclinical with 11 drugs in that stage. The Monkeypox pipeline has 22 drugs in development by companies and one by universities/ institutes. Some of the companies in the Monkeypox pipeline products market are: Tonix Pharmaceuticals Holding, BioNTech and GeoVax Labs.

The key targets in the Monkeypox pipeline products market include 2019 Novel corona Virus Spike Glycoprotein (E2 or Peplomer Protein or S), Bacterial Cell Membrane, and Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1).

The key mechanisms of action in the Monkeypox pipeline product include Bacterial Cell Membrane Disruptor with one drug in Discovery. The Monkeypox pipeline products include 11 routes of administration with the top ROA being Oral and nine key molecule types in the Monkeypox pipeline products market including mRNA Vaccine, and Small Molecule.

Monkeypox overview

Mpox, caused by the monkeypox virus, is an infectious disease presenting with a painful rash, fever, and enlarged lymph nodes. While most individuals fully recover, some may experience severe illness. Person-to-person transmission occurs through direct contact with infectious skin or lesions, including those in the mouth or genitals. Symptoms manifest from 1-21 days after exposure, lasting 2-4 weeks or longer in individuals with weakened immune systems. Diagnosis involves detecting viral DNA with a polymerase chain reaction (PCR) test. Treatment focuses on rash care, pain management, and complication prevention. Early supportive care is crucial. Vaccination is a preventive measure against mpox.

For a complete picture of Monkeypox’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.